Free Trial
NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Price, News & Analysis

Akebia Therapeutics logo
$2.38 +0.13 (+5.53%)
As of 03:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Akebia Therapeutics Stock (NASDAQ:AKBA)

Key Stats

Today's Range
$2.18
$2.37
50-Day Range
$1.69
$2.39
52-Week Range
$0.80
$2.48
Volume
3.64 million shs
Average Volume
2.68 million shs
Market Capitalization
$520.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75
Consensus Rating
Buy

Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Remove Ads

Akebia Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

AKBA MarketRank™: 

Akebia Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 247th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Akebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Akebia Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Akebia Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Akebia Therapeutics is -9.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Akebia Therapeutics is -9.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Akebia Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.11% of the float of Akebia Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akebia Therapeutics has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Akebia Therapeutics has recently decreased by 0.67%, indicating that investor sentiment is improving.
  • Dividend Yield

    Akebia Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akebia Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.11% of the float of Akebia Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akebia Therapeutics has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Akebia Therapeutics has recently decreased by 0.67%, indicating that investor sentiment is improving.
  • News Sentiment

    Akebia Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Akebia Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 26 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $589,216.00 in company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of Akebia Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 33.92% of the stock of Akebia Therapeutics is held by institutions.

  • Read more about Akebia Therapeutics' insider trading history.
Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKBA Stock News Headlines

Akebia Therapeutics' (AKBA) "Buy" Rating Reiterated at HC Wainwright
Elon Warns “America Is Broke”. Trump’s Plan Inside.
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
Akebia price target raised to $6 from $4 at Piper Sandler
Q4 2024 Akebia Therapeutics Inc Earnings Call
Akebia reports Q4 EPS (10c) vs 0c last year
See More Headlines

AKBA Stock Analysis - Frequently Asked Questions

Akebia Therapeutics' stock was trading at $1.90 at the beginning of 2025. Since then, AKBA shares have increased by 19.2% and is now trading at $2.2650.
View the best growth stocks for 2025 here
.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its earnings results on Thursday, March, 13th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05. The biopharmaceutical company had revenue of $46.50 million for the quarter, compared to analysts' expectations of $37.36 million.

Akebia Therapeutics' top institutional investors include Vanguard Group Inc. (4.99%), Geode Capital Management LLC (2.20%), Renaissance Technologies LLC (1.75%) and Northern Trust Corp (0.77%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, David A Spellman, Nicholas Grund and Richard C Malabre.
View institutional ownership trends
.

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and Exxon Mobil (XOM).

Company Calendar

Last Earnings
3/13/2025
Today
3/17/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKBA
Employees
430
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.75
High Stock Price Target
$7.50
Low Stock Price Target
$6.00
Potential Upside/Downside
+198.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-51,920,000.00
Pretax Margin
-27.08%

Debt

Sales & Book Value

Annual Sales
$169.88 million
Price / Cash Flow
N/A
Book Value
($0.16) per share
Price / Book
-14.13

Miscellaneous

Free Float
209,236,000
Market Cap
$493.09 million
Optionable
Optionable
Beta
0.94

Social Links

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:AKBA) was last updated on 3/17/2025 by MarketBeat.com Staff
From Our Partners